ATRA | tickerfilter.com

Fundamental analysis

36%

Profitability 43%

Dept financing 25%

Liquidity 42%

Performance 31%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

6.09%

1 Month

12.10%

3 Months

-12.44%

6 Months

-17.10%

1 Year

924.92%

2 Year

-89.20%

Key data

Stock price

$7.32

P/E Ratio

0.00

DAY RANGE

$7.10 - $7.67

EPS

-$7.96

52 WEEK RANGE

$0.37 - $18.70

52 WEEK CHANGE

$924.92

MARKET CAP

76.662 M

YIELD

N/A

SHARES OUTSTANDING

4.915 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

-0.62

PUBLIC FLOAT

AVERAGE 10 VOLUME

$50,838

AVERAGE 30 VOLUME

$52,478

Company detail

CEO: Pascal Touchon
Region: US
Website: atarabio.com
Employees: 330
IPO year: 2014

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing

Atara Biotherapeutics, Inc. develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

ATRA - Atara Biotherapeutics, Inc.